explore -WSS

explore

author：explore 2025-09-27 15:20:48 - browse：336

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Telehealth options flood the market as retailers push virtual care

focus

WSS

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Senate panel to vote on hospitals, PBMs, prisoner care

Artificial intelligence use in health care faces greater scrutiny in 2024

Why don't Americans have at

Having children helps parents live longer, especially after age 80

Artificial intelligence use in health care faces greater scrutiny in 2024

explore

explore

focus

Sports medicine is finally prioritizing gender equality

Physician subsidies by hospitals soar in wake of No Surprises Act

Sports medicine is finally prioritizing gender equality

Artificial intelligence use in health care faces greater scrutiny in 2024

Trump demands the U.S. pay no more for drugs than other countries … again

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Meta's Zuckerberg and Chan on track to put $50 billion into science

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

explore

Artificial intelligence use in health care faces greater scrutiny in 2024

Study gives hint on South Asians’ higher risk of cardiovascular disease

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Eli Lilly to pay $200M for Beam’s stake in gene

Doctors on social media are being harassed and cyberbullied

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

focus

hotspot

leisure time

explore